Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hormonal treatments can help with acne, especially in women, by lowering androgen levels or blocking their effects.

This article reviews the hormonal and medication-related factors associated with acne development but does not present new research findings.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

Acne is caused by genetics, diet, hormones, and bacteria, with treatments not yet curative.

This review concludes that antiandrogens with ovarian suppression may significantly improve hirsutism and androgenetic alopecia in women with PCOS, but treatment needs to continue unless the underlying PCOS cause is addressed.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This article reviews mechanisms by which herbal ingredients may stimulate or inhibit hair growth, and it reports no new clinical findings while suggesting potential for developing hair loss treatments.

This study found that the combination of spironolactone and finasteride significantly improved hirsutism scores more than spironolactone alone in women, with similar side-effect profiles between treatments.

This article reviews the hormonal pathogenesis and treatment strategies for acne vulgaris, particularly in women with severe or treatment-resistant cases, associating it with hormonal imbalances and hyperandrogenism.

This study found that both finasteride and flutamide effectively reduced hirsutism in women with polycystic ovary syndrome, decreasing the Ferriman-Gallwey score and hair diameter without significant side effects.

This study found that topical finasteride and flutamide both significantly reduced sebaceous gland growth and decreased prostatic weights in hamsters, indicating systemic effects despite local application.

This review discusses the use of antiandrogen therapy in dermatology, covering treatments for conditions like acne, hirsutism, and androgenic alopecia but reports no new clinical findings.

The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.

This study found that combining Flutamide and an LHRH agonist in adult male rats effectively inhibited prostatic growth and reduced androgen-sensitive prostatic activity markers to levels similar to castrated rats.

In this study, microneedles combined with finasteride nanostructured lipid carriers (FIN-NLC-MNs) were found to enhance skin penetration and specifically target hair follicles, promoting hair growth and gene regulation in androgenetic alopecia.

This study found that Dutasteride, a 5α-reductase inhibitor, demonstrated neuroprotective effects by preventing the MPTP-induced decline of dopaminergic markers in a Parkinson's disease mouse model.

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

This review explores various hormone influences on hair growth and loss beyond androgens, noting that clinical hormone therapies for aging may impact hair due to associated hormone level reductions, but reports no new empirical results.

This study identified new potential targets and indications for several marketed drugs using in silico profiling, suggesting opportunities for drug repositioning.

This review discusses various anti-androgen treatments for hirsutism, including androgen receptor blockers and inhibitors, and emphasizes the role of diagnosis in selecting the most appropriate therapy, but reports no new clinical results.

This article reviews the use of hormonal therapies in dermatology, specifically focusing on their pathophysiologic rationale, indications, commonly used drugs, and pretreatment evaluations, and it reports no new research findings.

This review discusses the etiology, diagnosis, and management strategies for hirsutism, noting that serious underlying disorders are rare and emphasizing targeted treatment to manage testosterone's effects.

This review discusses the role of the androgen receptor in breast cancer diagnosis and treatment, and notes a lack of new research results on its therapeutic potential.

This review discusses emerging targets for developing drugs to treat hair loss and reports no new clinical results; the authors emphasize the potential for therapies that regenerate hair follicles.

This study found that adding low-dose dutasteride to ongoing finasteride treatment significantly improved hair density in a patient with androgenetic alopecia.

This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This review discusses current challenges in selective androgen receptor modulator discovery and preclinical evaluation and reports no new results, emphasizing the need for basic research to improve safety and selectivity.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.